Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ribitol is a naturally occurring five-carbon sugar alcohol (pentose alcohol), also known as adonitol. It is formed by the reduction of ribose and occurs in some plants and Gram-positive bacteria as part of teichoic acids. Ribitol is a component of the structure of riboflavin and flavin mononucleotide. As an experimental therapy for certain muscular dystrophies—specifically those related to mutations in fukutin-related protein (FKRP)—ribitol acts as a pre-substrate for glycosyltransferase enzymes involved in the functional glycosylation of α-dystroglycan. Oral administration has been shown to restore matriglycan expression on α-dystroglycan in animal models with FKRP mutations and improve muscle pathology and function dose-dependently[4][6]. Ribitol has received orphan drug designation in Europe for this indication[7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ribitol.